INGELHEIM, Germany--(BUSINESS WIRE)--Jun 16, 2015--Today, The Lancet published results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa R (dabigatran etexilate) by its specific reversal agent idarucizumab. The study showed that idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa R. The data support the specific reversal agent as a highly targeted treatment option if reversal of the anticoagulant effect is needed, e.g. for urgent interventions. 1 Idarucizumab was granted Breakthrough Therapy Designation by the U.S. FDA 2 and has recently been submitted for approval to the FDA, EMA and Health Canada. 3 Boehringer Ingelheim pursues accelerated procedures with all three regulatory authorities. 3
In the healthy volunteer study now published in The Lancet, participants first received Pradaxa R and then idarucizumab. The specific reversal agent was given two hours after the last dose of Pradaxa R, when dabigatran concentrations were at peak levels. After a five-minute infusion of idarucizumab, anticoagulation was immediately reversed back to baseline levels. The reversal effect was sustained for more than 24 hours for all doses of 2g and above. Idarucizumab was well tolerated by the study participants. 1
"The data now published in The Lancet show in an impressive manner how effective idarucizumab was for reversing Pradaxa R in healthy volunteers", said Professor Jorg Kreuzer, Vice President Medicine Therapeutic Area Cardiovascular, Boehringer Ingelheim. "Once approved, the availability of a specific reversal agent for a NOAC will be yet another landmark in anticoagulation care."
Similar results were also seen in elderly and renally impaired volunteers in a study presented at the Annual Meeting & Exposition of the American Society for Hematology in December 2014. 4 Boehringer Ingelheim is now evaluating idarucizumab in the RE-VERSE AD TM study, the first study to investigate a reversal agent to a non-vitamin K antagonist oral anticoagulant in patients. 5
*Idarucizumab is the recommended International Nonproprietary Name (INN). Idarucizumab is an investigational drug, which has not been approved for clinical use, and further safety and efficacy testing will be required.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the link below for 'Notes to Editors' and 'References': http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/16_june_2015_dabigatranetexilate.html
View source version on businesswire.com:http://www.businesswire.com/news/home/20150616005724/en/
CONTACT: Boehringer Ingelheim GmbH
Phone:+49 6132 ?V 77 141575
Fax:+49 6132 ?V 77 6601
KEYWORD: EUROPE GERMANY
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Boehringer Ingelheim GmbH
Copyright Business Wire 2015
PUB: 06/16/2015 03:00 AM/DISC: 06/16/2015 03:00 AM